Research programme: diabetes therapeutics and diagnostics - Affymetrix/Roche
Latest Information Update: 30 Aug 2006
At a glance
- Originator Affymetrix; Roche
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 30 Aug 2006 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
- 28 Oct 2005 ParAllele BioScience has been acquired and merged into Affymetrix
- 18 Sep 2003 Preclinical trials in Type-2 diabetes mellitus in USA (unspecified route)